Akums' introduction of a cost-effective hydroxyurea oral solution for sickle cell disease, offered to GoI, has the potential to transform treatment globally. This innovation, coupled with advancements in drug production quality, bolsters India's pharmaceutical standing and medical diplomacy efforts. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
